Medico Intercontinental Limited has delivered a strong financial performance for the third quarter of FY26, showcasing consistent growth across key metrics. The pharmaceutical company's latest results demonstrate resilience and operational efficiency in a competitive market environment.

Financial Performance Overview

The company's quarterly performance reflects steady business momentum with improved profitability metrics. Revenue growth was supported by robust operational activities, while cost management initiatives contributed to enhanced bottom-line performance.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Medico Intercontinental maintained its growth trajectory with comprehensive improvements across financial parameters. The extended period results underscore the company's ability to sustain performance momentum throughout the fiscal year.

Operational Highlights

The company's operational structure remained focused on its core pharmaceutical business segment. During Q3FY26, Medico Intercontinental operated as a single segment entity, maintaining its strategic focus on pharmaceutical operations. The company's cost structure showed disciplined management with total expenses of ₹1270.10 lakhs in Q3FY26 compared to ₹1084.96 lakhs in the corresponding previous quarter.

Corporate Governance and Compliance

The financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 14, 2026. The results have been prepared in accordance with Indian Accounting Standards (Ind AS) and have received an unmodified opinion from statutory auditors. The company maintains a paid-up equity share capital of ₹1000.00 lakhs with shares having a face value of ₹10 each.

Tax Management and Regulatory Compliance

Medico Intercontinental continues to evaluate tax optimization strategies under the current regulatory framework. The company has maintained its approach with existing income tax rates while assessing options available under section 115BAA of the Income Tax Act, 1961, as per the Taxation Laws (Amendment) Ordinance, 2019. Current tax expense for Q3FY26 stood at ₹22.61 lakhs compared to ₹15.53 lakhs in Q3FY25.

Medico Intercontinental Limited has announced that its Promoter and Managing Director significantly increased his shareholding through open market transactions. The pharmaceutical company disclosed this substantial acquisition under SEBI regulations on December 26, 2025.

Transaction Overview

Mr. Samir Dilipkumar Shah, Managing Director and Promoter of Medico Intercontinental Limited, acquired additional equity shares through open market purchase, triggering disclosure requirements under SEBI substantial acquisition regulations.

Shareholding Changes

The acquisition resulted in a notable increase in Mr. Shah's shareholding percentage in the company:

Regulatory Compliance

The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulatory framework requires disclosure when there is a substantial change in shareholding that crosses specified thresholds.

The company's equity share capital stands at ₹10.00 crores, with the total diluted share capital remaining unchanged post-acquisition. Mr. Shah communicated the transaction details to BSE Limited, where the company's shares are listed under scrip code 539938.

Persons Acting in Concert

The disclosure identified several Persons Acting in Concert (PAC) with the acquirer, including family members and related entities. The PAC group includes Dilipkumar Bhogilal Shah, Jay Sharadkumar Shah, Dineshkumar Sevantilal Shah, Siddharth Dinesh Shah, Bhartiben Dineshbhai Shah, and Shah Dinesh Sevantilal HUF, maintaining their collective 12.68% shareholding.

Company Profile

Medico Intercontinental Limited operates in the pharmaceutical sector with its registered office at 1-5th Floor, Aditraj Arcade, Near Hetvi Tower, 100 Ft Road, Satellite, Ahmedabad-380015. The company maintains compliance with all regulatory requirements through timely disclosures of material transactions by promoters and key management personnel.